| Name | R-10015 |
| Description | R-10015 is a highly potent and selective LIMK inhibitor that blocks LIMK by binding to the ATP-binding pocket. It inhibits human LIMK1 with an IC50 value of 38 nM. It also exerts broad-spectrum antiviral effects and may be used in HIV infection research. |
| In vitro | R10015 as a lead compound that blocks LIMK activity by binding to the ATP-binding pocket.?R10015 specifically blocks viral DNA synthesis, nuclear migration, and virion release.?In addition, R10015 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and herpes simplex virus 1 (HSV-1), suggesting that LIMK inhibitors could be developed as a new class of broad-spectrum antiviral drugs. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (12.17 mM), Sonication is recommended.
DMSO : 62.5 mg/mL (152.12 mM), Sonication is recommended.
|
| Keywords | ReverseTranscriptase | Reverse Transcriptase | R-10015 | R10015 | R 10015 | LIMKs | LIMKinase | LIM Kinase (LIMK) | LIM Kinase | Inhibitor | inhibit | human LIMK1 |
| Inhibitors Related | Stavudine | Emtricitabine | Lamivudine | Tenofovir Disoproxil Fumarate | Tenofovir alafenamide | Methyl gallate | Daidzin | Oltipraz | Salicylanilide | Gramine | Telbivudine | Tenofovir |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Viral Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Infection Compound Library | Anti-Cancer Compound Library |
United States
